binx health Announces Appointment of UnitedHealth Group’s Optum Rx CFO Jeff Grosklags to its Board of Directors

BOSTON–(BUSINESS WIRE)–binx health, a health technology and diagnostics company that makes routine testing easier by enabling access to care where people live, work, study and shop, today announced the appointment of Jeff Grosklags, an accomplished industry leader and UnitedHealth Group’s Optum Rx Chief Financial Officer (CFO) to its Board of Directors. For the past 16 years, Grosklags has held senior financial roles with Optum and UnitedHealth Group.

“We are thrilled to welcome Jeff to the binx Board of Directors given his decades of leadership in business and healthcare, and his passion for access to care,” said Jeff Luber, CEO of binx health. “In a rapidly changing environment for healthcare delivery, we are fortunate to have the breadth of talent we have on the binx board and we know that Jeff will be a huge addition to our mission of ‘Everywhere Care’.”

With over 25 years of leadership experience, Grosklags brings significant strategic, operational and financial expertise to the business. He is currently Chief Financial Officer of Optum Rx, a UnitedHealth Group company, one of the largest pharmaceutical care services companies in the United States, serving 60 million Americans nationwide, 67,000 network pharmacies and over $100 billion in managed drug spend. Prior to becoming Chief Financial Officer of Optum Rx, Grosklags held several leadership roles within the UnitedHealth Group, including Chief Financial Officer of Optum Health Care Solutions, Optum Health Care Delivery and Chief Operating Officer and Director financial institution of Optum Financial Services. Prior to joining UnitedHealth Group in 2006, he held several leadership positions at Metris Companies, including CFO of the credit card business and senior vice president of finance. Grosklags previously served as lead auditor for Deloitte and holds a degree in business administration with a concentration in accounting from the University of St. Thomas.

“Patients are looking beyond clinics and demanding care solutions that fit their busy lifestyles,” Grosklags said. “binx is well positioned to play an important role in this era of healthcare with its commitment to using innovation and technology to increase access and equity in healthcare. I am delighted to join the binx health board of directors.

binx health strives to improve sexual health and well-being by providing convenient access to high-quality testing that prioritizes clinical integrity and consumer convenience. binx’s healthcare solutions are designed to remove barriers to testing with on-site, point-of-care solutions and discreet, patient-tailored home sample collection offerings to reach patients “everywhere”. In response to the pandemic, in addition to sexual health and wellness, binx health has added COVID-19 programs that have proven essential in helping partners track, record and manage compliance with testing protocols.

About binx health

binx health is a health technology and diagnostics company that makes routine testing easier by enabling access to care where people live, work, study and shop. The Company works with large corporate partners and institutions that have access to large patient populations and have a significant interest in providing or facilitating better healthcare to provide access and enable more streamlined delivery of HIV testing. diagnosis and treatment. Its omnichannel platform includes point of service io platform, which puts central lab-grade testing solutions in the hands of clinicians around the world, and the suite of physician-mediated, medical-guideline-based home sample collection offerings, which bring high-quality testing, population health tools, and seamless digital onboarding capability to those unable or unwilling to visit a clinic.

by binx io is the first-ever FDA-cleared, CLIA-exempt point-of-care tool for the detection of chlamydia and gonorrhea from male and female specimens that provides central lab performance results in approximately 30 minutes. Its platform is highly flexible, easy to use and fast, delivering point-of-care molecular answers with central lab-grade performance and enabling single-visit testing and treatment for the first time. For more information, visit

Comments are closed.